2,338 reports of this reaction
3.3% of all GEMCITABINE reports
#6 most reported adverse reaction
ANAEMIA is the #6 most commonly reported adverse reaction for GEMCITABINE, manufactured by Accord Healthcare Inc.. There are 2,338 FDA adverse event reports linking GEMCITABINE to ANAEMIA. This represents approximately 3.3% of all 70,539 adverse event reports for this drug.
Patients taking GEMCITABINE who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is moderately reported among GEMCITABINE users, representing a notable but not dominant share of adverse events.
In addition to anaemia, the following adverse reactions have been reported for GEMCITABINE:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 2,338 FDA reports for GEMCITABINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 3.3% of all adverse event reports for GEMCITABINE, making it a notable side effect.
If you experience anaemia while taking GEMCITABINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.